-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 WmsZQfxHwNzig6k3xf4yQZLtX7XupuNhrAzd1jfQXWD60/G60S8oaLInLPyjbSgP
 jbKQCvf5cWVKbYfFMeipKA==

<SEC-DOCUMENT>0001085037-06-000078.txt : 20060118
<SEC-HEADER>0001085037-06-000078.hdr.sgml : 20060118
<ACCEPTANCE-DATETIME>20060118130541
ACCESSION NUMBER:		0001085037-06-000078
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20060112
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20060118
DATE AS OF CHANGE:		20060118

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PLURISTEM LIFE SYSTEMS INC
		CENTRAL INDEX KEY:			0001158780
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				980351734
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31392
		FILM NUMBER:		06535054

	BUSINESS ADDRESS:	
		STREET 1:		MATAM ADVANCED TECHNOLOGY PARK
		STREET 2:		BUILDING NO. 20
		CITY:			HAIFA
		STATE:			L3
		ZIP:			31905
		BUSINESS PHONE:		972-4-850-1080

	MAIL ADDRESS:	
		STREET 1:		MATAM ADVANCED TECHNOLOGY PARK
		STREET 2:		BUILDING NO. 20
		CITY:			HAIFA
		STATE:			L3
		ZIP:			31905

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AI SOFTWARE INC
		DATE OF NAME CHANGE:	20010906
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k011206.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "f8k011206.pdf">


<HTML>
<HEAD>
   <TITLE>f8k011206.pdf -- Converted by SECPublisher 4.0, created by BCL Technologies Inc., for SEC Filing</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY bgcolor="#ffffff">
<!--$$/page=--><A name=page_1></A>
<P align=center>
<TABLE>

  <TR>
    <TD noWrap align=middle><B><FONT face=serif size=2
     >UNITED STATES SECURITIES AND</FONT></B><BR><B><FONT
      face=serif size=2>EXCHANGE
      COMMISSION</FONT></B><BR><B><FONT face=serif size=2
     >Washington, D.C. 20549</FONT></B><BR></TD></TR></TABLE></P>
<P align=center>
<TABLE>

  <TR>
    <TD noWrap align=middle><B><FONT face=sans-serif
     >FORM 8-K</FONT></B><BR></TD></TR></TABLE></P>
<P align=center><B><FONT face=serif size=2>CURRENT
REPORT<BR></FONT></B><FONT face=serif size=2
>Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of
1934</FONT></P>
<P align=center><FONT face=serif size=2>Date of
Report (Date of earliest event reported) </FONT><B><FONT face=serif size=2
BASEFACE="serif">January 12, 2006</FONT></B></P>
<P align=center>
<TABLE>

  <TR>
    <TD noWrap align=middle><B><FONT face=serif size=2
     >PLURISTEM LIFE SYSTEMS, INC.</FONT></B><BR><FONT face=serif
      size=2>(Exact name of registrant as
      specified in its charter)</FONT><BR></TD></TR></TABLE></P>
<P align=left><B><FONT face=serif size=2
>Nevada<BR></FONT></B><FONT face=serif size=2
>(State or other jurisdiction of incorporation)</FONT></P>
<P align=left><B><FONT face=serif size=2
>001-31392<BR></FONT></B><FONT face=serif size=2
>(Commission File Number)</FONT></P>
<P align=left><B><FONT face=serif size=2
>98-0351734<BR></FONT></B><FONT face=serif size=2
>(IRS Employer Identification No.)</FONT></P>
<P align=left><B><FONT face=serif size=2>MATAM
Advanced Technology Park, Building No. 20, Haifa, Israel
31905<BR></FONT></B><FONT face=serif size=2
>(Address of principal executive offices and Zip Code)</FONT></P>
<P align=left><B><FONT face=serif size=2
>011-972-4-850-1080<BR></FONT></B><FONT face=serif size=2
BASEFACE="serif">Registrant's telephone number, including area
code</FONT></P>
<P align=left><B><FONT face=serif size=2>Not
Applicable<BR></FONT></B><FONT face=serif size=2
>(Former name or former address, if changed since last
report)</FONT></P>
<P align=left><FONT face=serif size=2>Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:</FONT></P>
<P align=left><FONT face=serif size=2>[ ] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)</FONT></P>
<P align=left><FONT face=serif size=2>[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a -12)</FONT></P>
<P align=left><FONT face=serif size=2>[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d -2(b))</FONT></P>
<P align=left><FONT face=serif size=2>[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e -4(c))</FONT></P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0
>

  <TR vAlign=bottom>
    <TD align=left width="100%"><B><FONT
      face="Times New Roman" size=2
     >Item 7.01 Regulation FD Disclosure</FONT></B>&nbsp;
  </TD></TR></TABLE><BR>
<P align=left><FONT face=serif size=2>On January
12, 2006, the Registrant announced that it has formulated a cell graft to
provide an efficient alternative to the standard procedure of bone marrow
transplantation. The cell graft is presently in pre-clinical trials.</FONT></P>
<TABLE cellSpacing=0 cellPadding=0 width="100%" border=0
>

  <TR vAlign=bottom>
    <TD align=left width="99%" colSpan=2
     ><B><FONT face="Times New Roman" size=2
     >Item 9.01 Financial Statements and
      Exhibits</FONT></B>&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD align=left width="5%">
      <P><FONT face="Times New Roman" size=2
     ><BR>99.1</FONT>&nbsp; </P></TD>
    <TD align=left width="94%"><FONT face="Times New Roman"
      size=2>News Release dated January 12,
      2006.</FONT>&nbsp; </TD></TR></TABLE><BR>
<P align=left><FONT face=serif size=1
></FONT>&nbsp;</P>
<HR align=center width="100%" noShade SIZE=2>
<!--$$/page=--><A name=page_2></A>
<P align=center>
<TABLE>

  <TR>
    <TD noWrap align=middle><FONT face=serif size=2
     >- 2 -</FONT><BR></TD></TR></TABLE></P>
<P align=center>
<TABLE>

  <TR>
    <TD noWrap align=middle><B><FONT face=serif size=2
     >SIGNATURES</FONT></B><BR></TD></TR></TABLE></P>
<P align=left><FONT face=serif size=2>Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.</FONT></P>
<P align=left>
<TABLE>

  <TR>
    <TD noWrap><B><FONT face=serif size=2
     >PLURISTEM LIFE SYSTEMS,
INC.</FONT></B><BR></TD></TR></TABLE></P>
<P align=left>
<TABLE>

  <TR>
    <TD noWrap><FONT face=serif size=2>/s/ Zami
      Aberman</FONT><BR><FONT face=serif size=2
     >Zami Aberman</FONT><BR><FONT face=serif size=2
     >Chief Executive Officer</FONT><BR><FONT
      face=serif size=2>Date: January 12,
      2006</FONT><BR></TD></TR></TABLE></P>
<P align=left><FONT face=serif size=1
></FONT>&nbsp;</P>
<HR align=center width="100%" noShade SIZE=2>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>ex99-1f8k011206.htm
<DESCRIPTION>EXHIBIT 99.1 - NEWS RELEASE
<TEXT>
<!DOCTYPE HTML PUBLIC "ex99-1f8k011206.pdf">


<HTML>
<HEAD>
   <TITLE>ex99-1f8k011206.pdf -- Converted by SECPublisher 4.0, created by BCL Technologies Inc., for SEC Filing</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY bgcolor="#ffffff">
<!--$$/page=--><A name=page_1></A>
<P align=right>
<TABLE>

  <TR>
    <TD noWrap align=right><FONT face=sans-serif>Exhibit
      99.1</FONT><BR></TD></TR></TABLE></P>
<P align=left><B><FONT face=sans-serif>Pluristem Announces
Advanced Engineered Cell Graft to Improve Resurgence of the Hematopoietic Stem
Cells in Bone Marrow for Cancer Patients </FONT></B></P>
<P align=center><B><I><FONT face=sans-serif size=2
>-Pre-Clinical Animal Model Testing Underway-</FONT></I></B></P>
<P align=left><B><FONT face=sans-serif>Haifa, Israel -
January 12, 2005-- Pluristem Life Systems, Inc. (OTC</FONT></B><B><FONT
face=sans-serif>BB:PLRS), </FONT></B><B><I><FONT
face=sans-serif>a biotechnology company dedicated to the
commercialization of cell therapy products, today announced that the Company has
formulated a cell graft to provide an efficient alternative to the standard
procedure of bone marrow transplantation (BMT). The cell graft is presently in
preclinical trials. The </FONT></I></B><B><FONT face=sans-serif
BASEFACE="sans-serif">development of this </FONT></B><B><I><FONT face=sans-serif
BASEFACE="sans-serif">new advanced engineered graft that replenishes the bone
marrow of blood cancer patients can save the lives of million of
people.</FONT></I></B></P>
<P align=left><FONT face=sans-serif size=2
>Although the field of stem cell technology holds great promise, the
transplantation of HSC into patients with hematological malignancies remains the
</FONT><B><FONT face=sans-serif size=2
>only</FONT></B><FONT face=sans-serif size=2
> presently FDA-approved clinical procedure. Critical shortfall in
the supply of matched tissue for transplantation creates an urgent need for
alternative sources of hematopoietic stem cells (HSCs). Our procedures are not
yet approved. </FONT></P>
<P align=left><FONT face=sans-serif size=2
>Therefore, the Company has launched an extensive experimental
program in a relevant animal model to validate the usefulness and prove the
superiority of its technology over standard-of-care protocols and, the Company
contends, could rival competitor&#146;s models. </FONT></P>
<P align=left><FONT face=sans-serif size=2
>Pluristem has patented a technology for efficient expansion of HSCs
for bone marrow transplantation from Umbilical Cord Blood (UCB). The
</FONT><FONT face=sans-serif size=2
>uniqueness</FONT><FONT face=sans-serif size=2
> of this expansion technology is its ability to mimic the
physiological bone marrow environment by using two independent cell types,
Mesenchymal and HSCs, that are co-cultivated on a 3-D scaffold. Mesenchymal
cells that are abundantly present in human adult tissues (like fat or placenta)
and HSCs from UCB are being co-cultivated in our proprietary bioreactor system
that is devoid of supplemental cytokines and growth factors. The cell population
produced by this expansion technology is highly enriched by a very primitive
subset of hematopoietic cells (characterized as CD34+CD38-). It is well
established that these cells are essential for efficient repopulation of the
bone marrow of a cancer patient. Additionally, potentially harmful cytokines are
not being employed during the cultivation phase. This eliminates risks
associated with the use of cytokines that was conveyed in several scientific
papers and by a recent article published in Nature Biotechnology (Dec
2005).</FONT></P>
<P align=left><FONT face=sans-serif size=2
>Following </FONT><I><FONT face=sans-serif size=2
BASEFACE="sans-serif">ex-vivo</FONT></I><FONT face=sans-serif
size=2> expansion of HSCs, the entire mixture
of cells is being transplanted into a subject as an engineered graft. This
unique feature is expected to award Pluristem with an additional advantage over
its competitors - excellent engraftment. When presented to the bone marrow of a
transplanted patient as an engineered graft rather than as HSCs only, a better
engraftment of the donor HSCs is anticipated. This observation was published by
several leading authors and initially demonstrated to be effective in initial
animal model studies by the Company. </FONT></P>
<P align=left><FONT face=sans-serif size=2
>Dr. Ora Burger, Vice President of Development, stated, &#147;Pluristem
has literally reinvented the process of hematopoietic stem cell expansion and
engraftment through its novel approach. The field of stem cell expansion
technology and BMT is ripe for new approaches that hold the potential to save
millions of lives. Our laboratory in Haifa is a hot-bed of activity gaining
worldwide recognition while acting as an incubator for a host of stem cell
expansion technologies.&#148;</FONT></P>
<HR align=center width="100%" noShade SIZE=2>


<!--$$/page=-->
<A name="page_2"></A>

<P align="left">
<FONT size=2 face="sans-serif"> &#147;Our goal of moving from the &#147;research&#148; to the &#147;development&#148; phase is starting to be fulfilled by this breakthrough and previously announced animal model
studies which we plan to bring to the clinic as expeditiously as practicable&#148;, stated Zami Aberman, CEO.</FONT></P>
<P align="left">
<FONT size=2 face="sans-serif">&#147;The Company plans on presenting its finding in a number of scientific conferences throughout the year, furthering validation of these technological processes while we continue to
go on the road to bring our new message to the investment community,&#148; Aberman concluded.</FONT></P>
<P align="left">
<FONT size=2 face="serif">Safe Harbor Statement</FONT></P>
<P align="left">
<FONT size=2 face="serif">This press release contains statements, which may constitute "forward&#45;looking statements". Those statements include statements regarding the intent, belief or current expectations of
Pluristem Life Systems, Inc., and members of our management as well as the assumptions on which such statements are based. Forward&#45;looking statements in this release include statements that include Pluristem&#146;s technology eliminates risks
associated with the use of potentially harmful cytokines; that development of our new advanced engineered graft that replenishs the bone marrow of blood cancer patients can save lives of million of people; that our experiments may validate
usefulness and prove superiority of our technology over standard&#45;of&#45;care protocols could rival competitor&#146;s models; that we expect to have an advantage over competitors thourgh excellent engraftment; that we plan on presenting our
findings in a number of scientific conferences throughout the year, furthering validation of these technological processes; that we will bring animal trials to clinic as soon as practicable; that we are moving from the research to the development
stage; and that our platform for expanding stem cells offers breakthrough technology and multiple product opportunities in many therapeutic areas. Factors which may significantly change or prevent our forward looking statements from fruition include
that we may be unsuccessful in developing any products; that our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; that unforeseen scientific difficulties develop with our
process; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we
may not be able raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the
Company&#146;s latest 10&#45;KSB filed with the SEC.</FONT></P>

<HR noshade align="center" width="100%" size=2>


</BODY>

</HTML>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
